Switching telehealth GLP-1 providers: what the hype leaves out

What did @risinghealthreport actually say?

Maria, the creator behind this account, announced she switched telehealth providers from Emerge to a company called fifty.410 (stylized as "5410"). She praised their community of "60,000 patients," an app with live sessions, and "comprehensive blood work panels" that include at-home dry blood spot testing. She also disclosed, partway through the video, that she was hired as their social media manager. That disclosure came late and casually, buried after the praise.

She described her previous provider positively, saying she "thinks the world of" Emerge and lost a significant amount of weight during her year there. The hashtag compoundedglp1 signals she is using a compounded version of a GLP-1 receptor agonist, likely semaglutide or tirzepatide, though she uses the term "Tusefotide" throughout, which appears to be her personal nickname for tirzepatide.

Does the science back this up?

The core clinical claims here are thin. She does not actually make many pharmacological assertions, so there is not much to test against the literature. What she does claim, that GLP-1 agonists can drive meaningful weight loss over a year, is well-supported. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15 mg produced an average 22.5% body weight reduction over 72 weeks in adults with obesity.

Her enthusiasm for at-home bloodwork is harder to evaluate. Dry blood spot (DBS) testing has legitimate clinical applications and has been studied for lipid panels and metabolic markers (McDade et al., 2007, Demography). However, the analytical validity of DBS panels varies by lab, and the technology is not uniformly regulated or validated for all the markers telehealth companies market. "Getting to know a lot of things that are really important" is vague enough that it does not constitute a testable claim, but it does set expectations that may not always be met.

What did they get wrong (or right)?

She got the general weight loss claim right. A year on a GLP-1 agonist with meaningful results is consistent with clinical data, assuming appropriate dosing was managed by a licensed provider. Credit where it is due.

What she got wrong is the framing of this video as organic content. She disclosed her new employment at fifty.410 about two-thirds of the way through, after already delivering what amounts to a product endorsement. Under FTC guidelines, material connections, including paid employment, must be disclosed clearly and conspicuously at the start of content, not tucked into the middle of a casual update. The caption says nothing about her employment status at fifty.410 at all. That is a compliance problem, not a minor stylistic choice.

The use of "Tusefotide" as a nickname for tirzepatide also warrants a note. Tirzepatide is the active ingredient in Mounjaro and Zepbound. Compounded tirzepatide is not the same as those branded products. FDA has stated that compounded drugs are not FDA-approved and may differ in quality and concentration. Viewers should not assume equivalency.

What should you actually know?

If you are considering switching telehealth providers for GLP-1 therapy, the creator's personal satisfaction story is not a clinical recommendation. Legitimate telehealth prescribing requires a licensed provider, a documented medical history, and follow-up monitoring. Bloodwork is genuinely useful when managed by a clinician, but an at-home dry blood spot panel sold as a wellness service is not a substitute for clinical interpretation.

The FTC's 2023 updated guidance on endorsements requires influencers to disclose paid relationships before the promotional content begins, not after. Maria disclosed her employment mid-video and omitted it from the caption entirely. Platforms and regulators are increasingly scrutinizing exactly this pattern in health content.

Compounded GLP-1 medications occupy a legally and clinically distinct category from FDA-approved brand-name drugs. The FDA placed compounded semaglutide on its "demonstrably difficult to compound" list in 2024 as the shortage designation ended. The regulatory status of compounded tirzepatide remains in active litigation as of early 2025. Patients should confirm the legal and clinical status of any compounded GLP-1 product with their prescriber.